| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 237,40 | 237,50 | 15:55 | |
| 237,20 | 237,30 | 15:55 |
The share capital of the following share will be reduced at Nasdaq Copenhagen as of 21 April 2026 due to cancellation of treasury shares.
| ISIN | DK0010272202 |
| Name: | Genmab |
| Volume before change: | 64,250,721 shares (DKK 64,250,721) |
| Change: | 1,900,000 shares (DKK 1,900,000) |
| Volume after change: | 62,350,721 shares (DKK 62,350,721) |
| Face value: | DKK 1 |
| Short name: | GMAB |
| Orderbook ID: | 11143 |
For further information, please contact: Surveillance, tel. +45 33 93 33 66
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10:22 | Genmab A/S - cancellation of shares | The share capital of the following share will be reduced at Nasdaq Copenhagen as of 21 April 2026 due to cancellation of treasury shares.
ISIN
DK0010272202
Name:
Genmab
Volume... ► Artikel lesen | |
| Fr | Genmab schließt Kapitalherabsetzung um 1,9 Millionen Aktien ab | ||
| Fr | Genmab completes share capital reduction of 1.9 million shares | ||
| Fr | Genmab A/S Share Capital Reduction | Company Announcement COPENHAGEN, Denmark; April 17, 2026 - Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with... ► Artikel lesen | |
| Di | Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.... ► Artikel lesen |
